Every 10-K that AngioDynamics, Inc. (ANGO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ANGO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANGO filings page.
AngioDynamics amended its fiscal 2026 annual report solely to add inline XBRL tagging to Part III information that was inadvertently incomplete; it says no other information was changed. Performance against fiscal 2026 cash-incentive targets included net sales of $320.2 million versus a $312 million target and adjusted EBITDA of $18.2 million versus a $10.5 million target. The compensation committee credited 100% attainment for corporate objectives, resulting in cash incentive payouts equal to 180% of target for each named executive officer.
President and Chief Executive Officer James C. Clemmer announced his intention to retire on the earlier of a successor CEO’s appointment or November 30, 2026; by mutual agreement, the date may be extended month to month until a successor is found. His transition agreement provides continued vesting of previously issued equity awards until the later of the end of his service as a consultant or director. After that, stock options and service-based restricted stock units immediately vest, while performance-based restricted stock units remain eligible to vest under their terms. For fiscal 2026, 64% of the CEO’s target total compensation was performance-based.
AngioDynamics, Inc. amended its fiscal 2026 annual report to add Part III disclosures on directors, governance and executive compensation. It states that no other items were amended or updated and that the original report otherwise remains unchanged.
For fiscal 2026, net sales were $320.2 million against a $312 million incentive target, and Adjusted EBITDA was $18.2 million against a $10.5 million target. Each of the five named executive officers received an annual cash incentive payout equal to 180% of target. Approximately 93.1% of votes cast, including abstentions, favored named executive compensation at the 2025 annual meeting; the committee kept its general approach for fiscal 2026.
Chief Executive Officer James C. Clemmer announced an intention to retire on the earlier of November 30, 2026, or the appointment of a successor, with a possible month-to-month extension by mutual agreement. Retention agreements provide Stephen A. Trowbridge, Laura Piccinini and Warren G. Nighan awards equal to 150% of base salary if they meet the stated employment condition or their position is eliminated without cause; other executive leadership team members are eligible for 50%.
AngioDynamics, Inc. reports on its medical technology business designing, manufacturing and selling devices used to treat cardiovascular disease and cancer. Products are organized into Med Tech (Auryon atherectomy, AlphaVac and AngioVac thrombectomy systems, NanoKnife IRE ablation, Solero microwave ablation) and Med Device lines.
The company has reshaped its portfolio by selling dialysis, BioSentry, PICC and Midline businesses and discontinuing RadioFrequency Ablation and Syntrax, while planning a shift of additional manufacturing to third-party partners, including Costa Rica, by the first quarter of fiscal 2027. NanoKnife received expanded FDA 510(k) clearance for prostate ablation and MDR CE mark approval covering pancreas, kidney, liver and prostate tumors.
AngioDynamics lists intense competition from large device makers, pricing pressure from group purchasing organizations, dependence on key suppliers and international distributors, complex global regulation and potential product-liability and compliance exposure as principal risks. It employed 632 people as of May 31, 2026, and its CEO has announced plans to retire by late 2026.